DGAP-Adhoc: INJEX Pharma AG: INJEX Pharma AG obtains Chinese SFDA registration for INJEX30 needle free injection system

INJEX Pharma AG / Key word(s): Miscellaneous

16.04.2013 10:13

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc Release: INJEX Pharma AG obtains Chinese SFDA registration for
INJEX30 needle free injection system

China, April 16, 2013 - INJEX Pharma AG is pleased to announce that
yesterday its wholly owned subsidiary INJEX Pharma GmbH has successfully
registered the INJEX30 needle free injection system with the Chinese State
Food and Drug Administration (SFDA), supported by its exclusive distributor
Hangzhou Hema Medical Equipment Co. Ltd. The SFDA is responsible for
regulating the market access of medical devices in the People's Republic of
China. The arduous approval process took more than 1.5 years and has
required a detailed documentation.

The registration is a significant milestone in the Company's efforts to
expand its offerings in key markets. One area of application is the use of
insulin for persons with diabetes. According to figures in the recent
Diabetes Atlas (5th edition, 2012) published by the International Diabetes
Federation, about one fourth of the 371 million people with diabetes live
in China. Hangzhou Hema Medical Equipment can immediately start marketing
the INJEX30 system.

For further information on INJEX Pharma AG and its subsidiaries, please
refer to www.injex.com.

For further questions please contact our Investor Relations team directly:
INJEX Pharma AG
Investor Relations Team

t: +49 89 24 41 18 - 223
f: +49 89 24 41 18 - 499
ir@injex.com

INJEX Pharma AG:
INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and
INJEX Vertrieb Deutschland GmbH are specialized in the development,
manufacturing and marketing in the medical technology segment and in the
cosmetics and beauty markets. The Group's core business areas are the
needle-free INJEX30 system and the product line SHIREEN in the beauty
market. The main markets of the Group are North America, China, India,
Russia and Europe.

---------------------------------------------------------------------------

Language: English
Company: INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Germany
Phone: +49 89 24 41 18 - 223
Fax: +49 89 24 41 18 - 499
E-mail: ir@injex.de
Internet: www.injex.de
ISIN: DE000A0STYL7
WKN: A0STYL
Listed: Regulierter Markt in Frankfurt (General Standard)

Notierung im Regulierten Markt vorgesehen / intended to be listed at Regulated
Market

End of Announcement DGAP News-Service

---------------------------------------------------------------------------